Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer

Lung Cancer

Volumn 73, Issue 3, 2011, Pages 332-337

  Zhu, Dongyuan ^a,b   Ma, Tinghang ^b   Niu, Zuoxing ^b   Zheng, Jinsong ^b   Han, Anqin ^b   Zhao, Shuqiang ^b   Yu, Jinming ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

18F FDG; Metabolic tumor volume; PET CT; Prognosis; Small cell lung cancer; Standardized uptake value

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79960892206     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.007     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Simon G., Ginsberg R.J., Ruckdeschel J.C. Small-cell lung cancer. Chest Surg Clin N Am 2001, 11:165-188. ix.
3. Johnson B.E., Janne P.A. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 2004, 18:309-322.
4. Simon M., Argiris A., Murren J.R. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004, 49:119-133.
5. Yip D., Harper P.G. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000, 28:173-185.
6. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. J Clin Oncol 1990, 8:1563-1574.
7. Sasaki R., Komaki R., Macapinlac H., Erasmus J., Allen P., Forster K., et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005, 23:1136-1143.
8. Davies A., Tan C., Paschalides C., Barrington S.F., O'Doherty M., Utley M., et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer 2007, 55:75-78.
9. Guo H., Zhu H., Xi Y., Zhang B., Li L., Huang Y., et al. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J Nucl Med 2007, 48:1251-1258.
10. Lee Y.J., Cho A., Cho B.C., Yun M., Kim S.K., Chang J., et al. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res 2009, 15:2426-2432.
11. Xie P., Yue J.B., Fu Z., Feng R., Yu J.M. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 2009, 21:1078-1082.
12. Seol Y.M., Kwon B.R., Song M.K., Choi Y.J., Shin H.J., Chung J.S., et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 2010, 49:201-208.
13. Roedl J.B., Halpern E.F., Colen R.R., Sahani D.V., Fischman A.J., Blake M.A. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 2009, 11:54-60.
14. La T.H., Filion E.J., Turnbull B.B., Chu J.N., Lee P., Nguyen K., et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009, 74:1335-1341.
15. Hyun S.H., Choi J.Y., Shim Y.M., Kim K., Lee S.J., Cho Y.S., et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2009, 17:115-122.
16. Chung M.K., Jeong H.S., Park S.G., Jang J.Y., Son Y.I., Choi J.Y., et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 2009, 15:5861-5868.
17. Xie P., Yue J.B., Zhao H.X., Sun X.D., Kong L., Fu Z., et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2009, 136:883-889.
18. Hong R., Halama J., Bova D., Sethi A., Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 2007, 67:720-726.
19. Zhong X., Yu J., Zhang B., Mu D., Zhang W., Li D., et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2009, 73:136-141.
20. Lee P., Weerasuriya D.K., Lavori P.W., Quon A., Hara W., Maxim P.G., et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007, 69:328-333.
21. Ball D.L., Fisher R., Burmeister B., Graham P., Joseph D., Penniment M., et al. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol 2006, 1:667-672.
22. Bradley J.D., Ieumwananonthachai N., Purdy J.A., Wasserman T.H., Lockett M.A., Graham M.V., et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002, 52:49-57.
23. Berghmans T., Dusart M., Paesmans M., Hossein-Foucher C., Buvat I., Castaigne C., et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008, 3:6-12.
24. Um S.W., Kim H., Koh W.J., Suh G.Y., Chung M.P., Kwon O.J., et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Lung Thorac Oncol 2009, 4:1331-1336.
25. Soret M., Bacharach S.L., Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007, 48:932-945.
26. Boellaard R., Krak N.C., Hoekstra O.S., Lammertsma A.A. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004, 45:1519-1527.
27. Westerterp M., Pruim J., Oyen W., Hoekstra O., Paans A., Visser E., et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007, 34:392-404.